Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma

NCT02120222 is registered in ClinicalTrials.gov with Kari Kendra as lead sponsor.

NCT NCT02120222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02120222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma
Lead sponsor
Kari Kendra
Phase
Phase 1
Overall status
Completed
Start date
August 22, 2014
Completion date
April 8, 2018
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent melanoma